PURPOSE: Eukaryotic translation initiation factor 4E (eIF4E) is overexpressed in many cancer and is emerging as a potential therapeutic target. Yet data on the expression of eIF4E in endometrial cancer are lacking. METHODS: Immunohistochemistry was used to evaluate the expression of eIF4E in 62 endometrial cancer surgical specimens. We subsequently evaluated whether inhibition of eIF4E by siRNA would have an impact on cell growth in endometrial cancer cell lines, using the MTT cell proliferation assay. RESULTS: According to a chosen cutoff value, 36 (58.1%) of 62 patient specimens scored as eIF4E positive. The positivity of eIF4E was significantly more frequent in tumors extending outside the uterus (stage III/IV vs. stage I/II, P = 0.027). Lastly, downregulation of eIF4E by siRNA reduced the growth of HEC-1A cells significantly but had a somewhat weaker effect in Ishikawa cells (P < 0.001). CONCLUSIONS: Expressions of eIF4E correlated with prognosis of endometrial adenocarcinomas. Our results suggest that eIF4E might be a promising therapeutic target in endometrial cancer.
PURPOSE:Eukaryotic translation initiation factor 4E (eIF4E) is overexpressed in many cancer and is emerging as a potential therapeutic target. Yet data on the expression of eIF4E in endometrial cancer are lacking. METHODS: Immunohistochemistry was used to evaluate the expression of eIF4E in 62 endometrial cancer surgical specimens. We subsequently evaluated whether inhibition of eIF4E by siRNA would have an impact on cell growth in endometrial cancer cell lines, using the MTT cell proliferation assay. RESULTS: According to a chosen cutoff value, 36 (58.1%) of 62 patient specimens scored as eIF4E positive. The positivity of eIF4E was significantly more frequent in tumors extending outside the uterus (stage III/IV vs. stage I/II, P = 0.027). Lastly, downregulation of eIF4E by siRNA reduced the growth of HEC-1A cells significantly but had a somewhat weaker effect in Ishikawa cells (P < 0.001). CONCLUSIONS: Expressions of eIF4E correlated with prognosis of endometrial adenocarcinomas. Our results suggest that eIF4E might be a promising therapeutic target in endometrial cancer.
Authors: Jeremy R Graff; Bruce W Konicek; Thomas M Vincent; Rebecca L Lynch; David Monteith; Spring N Weir; Phil Schwier; Andrew Capen; Robin L Goode; Michele S Dowless; Yuefeng Chen; Hong Zhang; Sean Sissons; Karen Cox; Ann M McNulty; Stephen H Parsons; Tao Wang; Lillian Sams; Sandaruwan Geeganage; Larry E Douglass; Blake Lee Neubauer; Nicholas M Dean; Kerry Blanchard; Jianyong Shou; Louis F Stancato; Julia H Carter; Eric G Marcusson Journal: J Clin Invest Date: 2007-09 Impact factor: 14.808
Authors: Vidya P Ramamurthy; Senthilmurugan Ramalingam; Andrew K Kwegyir-Afful; Arif Hussain; Vincent C O Njar Journal: Curr Opin Oncol Date: 2017-05 Impact factor: 3.645
Authors: Maria Anna Smolle; Piotr Czapiewski; Sylwia Lapińska-Szumczyk; Hanna Majewska; Anna Supernat; Anna Zaczek; Wojciech Biernat; Nicole Golob-Schwarzl; Johannes Haybaeck Journal: Int J Mol Sci Date: 2019-12-06 Impact factor: 5.923